课题基金 / 基金详情

Lineage Specific Effects of IL10 In Autoimmunity

Lineage Specific Effects of IL10 In Autoimmunity
IL10 在自身免疫中的谱系特异性作用
批准号:
8707595
负责人:
Terrence L Geiger
金额:
$41.13万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-08 至 2014-07-31

项目摘要

项目成果

Terrence L Geiger的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):IL 10是一种主要的抗炎细胞因子,在设定免疫应答幅度中至关重要。IL10或IL10R表达或功能的遗传变异与自身免疫性和炎性疾病的易感性相关。许多免疫调节疗法的功效是IL 10依赖性的。然而,用IL 10的药物治疗在几种疾病中几乎没有显示出益处,并且在一些实验环境中,用IL 10的过表达或药物治疗甚至可以促进自身免疫性炎症。我们假设IL 10的谱系特异性效应的差异可能部分解释其体内活性的变异性。为了剖析IL 10的谱系特异性,我们产生了IL 10受体的IL 10选择性链IL 10R?的条件性缺陷小鼠。在初步研究中,我们分析了IL 10 R?对自身免疫性疾病模型实验性变态反应性脑脊髓炎(EAE)中的T细胞、Foxp 3+调节性T细胞、B细胞和巨噬细胞的影响。我们的研究结果表明IL 10的促炎和抗炎功能以谱系依赖的方式分离。此外,IL 10在谱系内具有异质性作用,并且这些作用可能对该谱系的致病性具有相反的作用。在这个建议中,我们将使用EAE作为一个模型系统,以探讨IL 10的谱系特异性作用如何影响自身免疫的发展和进展。令人惊讶的是,我们证明了对IL 10的T细胞应答使EAE恶化。我们假设IL 10通过抑制其终末分化和促进其存活来帮助维持负责免疫病理学的效应T细胞(Teff)。在目的1中,我们将确定IL 10对T细胞的作用如何促进EAE的免疫病理学。我们将讨论IL 10介导的调节T细胞增殖,存活和记忆的机制,免疫环境如何影响IL 10的产生和作用,IL 10 R信号的质量,动力学和幅度如何影响其T特异性活动,以及IL 10影响T细胞反应的相关细胞来源。与Teff相反,Foxp3+调节性T细胞的IL 10应答抑制EAE。我们假设IL 10在炎症期间起到支持Treg寿命和抑制能力的作用。在目标2中,我们将分析IL 10对EAE期间Treg存活、增殖、成熟和功能的影响。IL 10在全球范围内限制EAE的严重程度,但其T细胞特异性作用促进疾病。在目标3中,我们将鉴定并开始表征负责IL 10在EAE中的缓解作用的细胞谱系。剖析IL 10 β在自身免疫过程中如何影响不同的细胞谱系,将为我们提供对IL 10调节作用的更好的机制理解,以及有助于通过IL 10途径调节炎症的新疗法的合理设计的见解。
英文摘要
DESCRIPTION (provided by applicant): IL10 is a predominantly anti-inflammatory cytokine that is critical in setting immune response amplitude. Genetic variation in IL10 or IL10R expression or function is associated with susceptibility to autoimmune and inflammatory diseases. The efficacy of many immunomodulatory therapies is IL10 dependent. Nevertheless, pharmacotherapy with IL10 has shown little benefit in several diseases, and in some experimental settings overexpression or pharmacologic treatment with IL10 can even promote autoimmune inflammation. We hypothesized that differences in the lineage specific effects of IL10 may in part explain the variability of its activity in vivo. To dissect IL10's lineage specifi actions, we generated mice conditionally deficient in the IL10-selective chain of the IL10 receptor, IL10R?. In preliminary studies, we analyzed deficiency of IL10R? on T cells, Foxp3+ regulatory T cells, B cells and macrophage in a model autoimmune disease, experimental allergic encephalomyelitis (EAE). Our findings indicated that pro- and anti- inflammatory functions of IL10 segregate in a lineage dependent manner. Further, IL10 has heterogeneous actions within a lineage, and these may have opposing effects on that lineage's pathogenicity. In this proposal we will use EAE as a model system to explore how the lineage specific effects of IL10 influence the development and progression of autoimmunity. We demonstrated that, surprisingly, the T cell response to IL10 worsened EAE. We hypothesize that IL10 helps sustain the effector T cells (Teff) responsible for immunopathology by inhibiting their terminal differentiation and promoting their survival. In Aim 1, we will determine how IL10's actions on T cells promote immunopathology in EAE. We will address mechanisms of IL10-mediated modulation of T cell proliferation, survival, and memory in vivo, how the immune environment influences the production and effects of IL10, how IL10R signal quality, kinetics, and magnitude influence its T-specific activities, and relevant cellular sources for IL10 affecting the T cell response. In contrast to Teff, the IL10 response of Foxp3+ regulatory T cells suppressed EAE. We hypothesize that IL10 acts to support Treg longevity and suppressive capacity during inflammation. In Aim 2 we will analyze IL10's influence on Treg survival, proliferation, maturation, and function during EAE. IL10 acts globally to limit EAE severity, yet its T cell-specific actions promote disease. In Aim 3 we will identify and begin to characterize the cell lineages responsible for IL10's palliative effects in EAE. Dissecting how IL10 variably influences different cell lineages during autoimmunity will provide us with an improved mechanistic understanding of IL10's regulatory actions, and insights that will aid in the rational design of ne therapeutics that modulate inflammation through the IL10 pathway.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI: 10.4049/jimmunol.1800016
发表时间: 2018-11-15
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Li B, Jones LL, Geiger TL]
通讯作者: Geiger TL
TREATMENT OF AUTOIMMUNITY WITH RECEPTOR-MODIFIED T CELLS
TREATMENT OF AUTOIMMUNITY WITH RECEPTOR-MODIFIED T CELLS
TREATMENT OF AUTOIMMUNITY WITH RECEPTOR-MODIFIED T CELLS
TREATMENT OF AUTOIMMUNITY WITH RECEPTOR-MODIFIED T CELLS
海外基金